|
|
|
|
Science Sparks @ ACTREC
|
 15th December 2025 |
Vol. No. 14 ; Issue No.713 |
|
|
Publications
|
|
1. Nandy K, Kamal P, Chopde A, Ostwal V, Ramaswamy A, Pawar A, Chaudhari V, Shrikhande SV, Bhandare MS (2025). Outcomes of pancreatoduodenectomy in underlying liver cirrhosis: a single institution experience and literature review. Langenbeck's Archives of Surgery.
2. Ektare P, Pai N, Jain K, Rane P, Singh VK, Shetty P, Moiyadi AV (2025). Perioperative neuropsychological assessment reveals dynamic changes in neurocognitive function following brain tumor surgery. Brain and Spine.
3. Patwardhan R, Rizvi Z, Gota V, Checker R, Singh B, Maurya D, Pal D, Ramani N, Kumar BK, Purohit V, Mathapati BS, Mullick J, Ghanty T, Gupta S, Joshi M, Madki S, Awasthi A, Sandur S, Sharma D (2025). First-in-human clinical trial of high-dose sodium copper chlorophyllin: Pharmacology and efficacy as a dual immunomodulatory/antiviral agent. Phytomedicine.
4. Sinha S, Ghosh Laskar S, Dhingra S, Kumar A, Mohanty S, Budrukkar A, Swain M, Bishnu PN, Joy I, Ali R, Kannan S, Mummudi N (2026). Avoiding adjuvant Prophylactic Neck irradiation in lateralized oral cavity cancer (APRON). Clinical Oncology. 49: 103980.
5. Dey P, Bishnu A, Patel J, Mishra S, Gadewal N, Ray P, Gupta S, De A (2025). Hotspot mutations in HER2 interfaces destabilize structure, causing breast cancer treatment failure. Oncogene.
Book Chapter
Viswalingam V, Kumar D, Pal K (2026). Cancer stem cells in resisting chemotherapy and the recurrence of glioblastoma multiforme. In: Kumar D, Sharma R(Eds.) Chemoresistance in Glioblastoma: Understanding and Management. Academic Press. Pp. 171-199.(ISBN 978-0-443-339-103).
|
|
|
|
|
Interesting Reads
|
|
Chilloux J, Brial F, Everard A, Smyth D, Andrikopoulos P, Zhang L, Plovier H, Myridakis A, Hoyles L, Moreno-Navarrete JM, Luque JL, Casagrande V, Menghini R, Ahmetaj-Shala B, Blancher C, Martinez-Gili L, Gencer S, Fearnside JF, Barton RH, Neves AL, Rothwell AR, Gérard C, Calderari S, Williamson MJ, Fuchs JE, Govada L, Boulangé CL, Patel S, Scott J, Thursz M, Chayen N, Glen RC, Gooderham NJ, Nicholson JK, Federici M, Fernández-Real JM, Gauguier D, Liu PP, Cani PD, Dumas ME (2025). Inhibition of IRAK4 by microbial trimethylamine blunts metabolic inflammation and ameliorates glycemic control. Nature Metabolism.
|
|
|
Video of the Week
|
|
| Deciphering Breast Cancer Spatial and Molecular Insights into Tumor Evolution |
|
| |
|
|
| |
|
|
|
|
Do You Know?
In 2001, Results of a clinical trial showed that the drug imatinib mesylate, which targets a unique protein produced by the Philadelphia chromosome, is effective against chronic myelogenous leukemia (CML).
|
|
|
|
Cancer News
|
| |
|
Scientists melt cancer’s hdden “Power Hubs” and stop tumor growth.
|
|
SciTechDaily, 11/12/2025
|
|
Researchers discovered that in a rare kidney cancer, RNA builds droplet-like hubs that act as growth control centers inside tumor cells. By engineering a molecular switch to dissolve these hubs, they were able to halt cancer growth completely...
|
| |
|
Simple supplement mix shows remarkable results in brain cancer.
|
|
Sciencedaily, 10/12/2025
|
|
New research is challenging one of medicine’s oldest assumptions: that cancer must be attacked to be cured. By treating glioblastoma patients with a simple combination of resveratrol and copper, the researchers found dramatic reductions in tumor aggressiveness, cancer biomarkers...
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
2025 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
|
|
